NAFLD患者的代谢亚型表现出不同的心血管风险特征
研究分析了1154例经活检证实NAFLD患者的血清代谢组,并与四种VLDL-TG分泌受损和一种分泌正常的小鼠模型比对。识别出A(47%)、B(27%)、C(26%)三种代谢亚型,亚型A的VLDL-TG水平与分泌率较低、10年CVD高风险比例较低、PNPLA3风险等位基因频率较低。
要点
- NAFLD可分为A、B、C三种代谢亚型,比例分别为47%、27%、26%。
- 亚型A的VLDL-TG及分泌率低于B和C,且血清TG、胆固醇、VLDL、小而密LDL5,6及残粒脂蛋白胆固醇较低。
- 亚型A的Framingham风险评分10年CVD高风险比例及PNPLA3风险等位基因频率较低。
核心结论
- 代谢组学特征可识别三种NAFLD亚型,独立于组织学疾病严重程度。
- 这些特征与已知CVD和遗传风险因素一致,亚型A表现出较低的心血管风险特征。
- 这可能解释肝脏与心血管结局的差异,提供临床相关的风险分层。
研究设计与样本
- 分析1154例经活检证实NAFLD个体的血清代谢组。
- 同时分析四种VLDL-甘油三酯分泌受损和一种VLDL-甘油三酯分泌正常的小鼠模型。
主要发现
- 三种代谢亚型A、B、C的比例分别为47%、27%、26%。
- 亚型A的代谢组与VLDL-TG分泌受损小鼠相似,亚型C与VLDL-TG分泌正常小鼠相似,亚型B为中间特征。
- NASH和纤维化患者比例在各亚型间相当,但亚型B和C肝酶较高。
- 亚型A的血清VLDL-TG水平和分泌率低于亚型B和C。
- 亚型A的VLDL-TG和VLDL-载脂蛋白B浓度与脂肪变性无关,而亚型B和C与这些参数相关。
关键数值与推荐
- 亚型A的血清TG、胆固醇、VLDL、小而密LDL5,6和残粒脂蛋白胆固醇低于亚型B和C。
- 亚型A的Framingham风险评分10年CVD高风险比例及PNPLA3 NAFLD风险等位基因频率较低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. APPROACH AND RESULTS: We analyzed serum metabolome from 1154 individuals with biopsy-proven NAFLD, and from four mouse models of NAFLD with impaired VLDL-triglyceride (TG) secretion, and one with normal VLDL-TG secretion. We identified three metabolic subtypes: A (47%), B (27%), and C (26%). Subtype A phenocopied the metabolome of mice with impaired VLDL-TG secretion; subtype C phenocopied the metabolome of mice with normal VLDL-TG; and subtype B showed an intermediate signature. The percent of patients with NASH and fibrosis was comparable among subtypes, although subtypes B and C exhibited higher liver enzymes. Serum VLDL-TG levels and secretion rate were lower among subtype A compared with subtypes B and C. Subtype A VLDL-TG and VLDL-apolipoprotein B concentrations were independent of steatosis, whereas subtypes B and C showed an association with these parameters. Serum TG, cholesterol, VLDL, small dense LDL5,6 , and remnant lipoprotein cholesterol were lower among subtype A compared with subtypes B and C. The 10-year high risk of CVD, measured with the Framingham risk score, and the frequency of patatin-like phospholipase domain-containing protein 3 NAFLD risk allele were lower in subtype A. CONCLUSIONS: Metabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification.
引用
- Martínez-Arranz I, Bruzzone C, Noureddin M, et al. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology. 2022. PMID: 35220605. doi:10.1002/hep.32427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。